logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Cemiplimab bests chemotherapy in untreated advanced NSCLC with high PD-L1

Phase 3 results suggest cemiplimab may be another treatment option.